Pepper, A. G., Zucchetto, A., Norris, K., Tissino, E., Polesel, J., Soe, Z., Allsup, D., Hockaday, A., Ow, P. L., Hillmen, P., Rawstron, A., Catovsky, D., Bulian, P., Bomben, R., Baird, D. M., Fegan, C. D., Gattei, V., & Pepper, C. (2021). Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, https://doi.org/10.1038/s41375-021-01322-1